Holen Sie sich die Stockscreener-App
4.34
0.23%
0.010
Handel nachbörslich:
4.34
Lifecore Biomedical Inc Aktie (LFCR) Neueste Nachrichten
Lifecore Biomedical Inc (LFCR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lifecore Biomedical Inc (LFCR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
LFCR|Lifecore Biomedical Inc|Price:4.330|Chg%:-0.100 - TradingKey
Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical - The National Law Review
Lifecore Biomedical, Inc. Revenue Breakdown – NASDAQ:LFCR - TradingView
Lifecore Biomedical Inc. (LFCR) Q1 2026 Earnings: EPS Misses Estimates by Wide Margin Amid Operational ChallengesBook Value Growth - dars.gov.et
LFCR|Lifecore Biomedical Inc|Price:4.340|Chg%:+0.010 - TradingKey
Lifecore Biomedical Inc (LFCR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lifecore Biomedical (LFCR) Q1 2026 earnings summary - Quartr
Lifecore Biomedical (LFCR) Proxy filing Summary - Quartr
LFCR Deadline: LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit - GuruFocus
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sahm
What Triggered Lifecore Biomedical's Recent Stock Plunge - Kavout | AI
New Lifecore Hire Gets 3,500 Stock Units Vesting in Three Years - Stock Titan
Lifecore Biomedical Inc (LFCR) Continues Winning Contracts, Ignored by the Market - Yahoo Finance
Lifecore Biomedical (LFCR) AGM 2026 Summary - Quartr
Lifecore Biomedical (LFCR) Q2 2024 earnings summary - Quartr
Lifecore Biomedical (LFCR) Q3 2024 earnings summary - Quartr
Lifecore Biomedical Inc. (LFCR) Q1 2026 Earnings: Deep EPS Miss Highlights Operational DifficultiesFull Year Guidance - dars.gov.et
Lifecore Biomedical (LFCR) Gains 3.17% as Stock Tests Key Resistance at $4.95FRAMA Signal - dars.gov.et
Lifecore Biomedical Inc. (LFCR) Drops Nearly 6% as Stock Tests Key Support LevelsFloat Adjusted Cap - dars.gov.et
Lifecore Biomedical (LFCR) Slips 3.17%: Testing Key Support at $4.65WMA Signal - dars.gov.et
LFCR Q1 2026 Earnings: EPS Misses Estimates Amid Operational ChallengesGross Profit Margin - dars.gov.et
LFCR Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Revenue Not DisclosedEarnings Risk Report - DonanımHaber
Craig-Hallum Maintains Lifecore Biomedical(LFCR.US) With Buy Rating - Moomoo
Lifecore Biomedical (LFCR) Stock Forum and Discussion - Moomoo
Form 13D/A LIFECORE BIOMEDICAL For: 2 July By Investing.com - Investing.com India
Form 13D/A Lifecore Biomedical For: 2 July By Investing.com - Investing.com Nigeria
Lifecore Biomedical faces $52.1M Series A preferred redemption due Dec. 28, 2026 - TradingView
Lifecore Biomedical (NASDAQ: LFCR) gets $52.1M preferred redemption requests - Stock Titan
[SCHEDULE 13D/A] LIFECORE BIOMEDICAL, INC. \DE\ Amended Major Shareholder Report - Stock Titan
(LFCR) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Lifecore Biomedical’s New Collaborations May Strengthen Long-Term Value ProspectsDownward Estimate Revision - dars.gov.et
Can Lifecore Biomedical, Inc. (LFCR) Unlock Long-Term Value Through Expanding Biopharma Collaborations? - Yahoo Finance
Is Now An Opportune Moment To Examine Lifecore Biomedical, Inc. (NASDAQ:LFCR)? - simplywall.st
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirt - The National Law Review
12 Best Low-Priced Pharma Stocks to Buy Right Now - Insider Monkey
Enterprise value to revenue forward of Lifecore Biomedical, Inc. – NASDAQ:LFCR - TradingView
Price to sales forward of Lifecore Biomedical, Inc. – SWB:LDE - TradingView
Price to book forward of Lifecore Biomedical, Inc. – NASDAQ:LFCR - TradingView
Price to sales forward of Lifecore Biomedical, Inc. – LSX:899376 - TradingView
Lifecore Biomedical, Inc. Actuals & Estimates (NASDAQ:LFCR) - TradingView
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biom - The National Law Review
Enterprise value to EBITDA forward of Lifecore Biomedical, Inc. – NASDAQ:LFCR - TradingView
Enterprise value to EBITDA forward of Lifecore Biomedical, Inc. – LSX:899376 - TradingView
Enterprise value to EBIT forward of Lifecore Biomedical, Inc. – NASDAQ:LFCR - TradingView
Price to earnings forward of Lifecore Biomedical, Inc. – LSX:899376 - TradingView
Lifecore Biomedical, Inc. Actuals & Estimates (GETTEX:LDE) - TradingView
Lifecore Biomedical, Inc. Actuals & Estimates (BOATS:LFCR) - TradingView
LFCR Forecast — Price Target — Prediction for 2027 - TradingView
LDE Forecast — Price Target — Prediction for 2027 - TradingView
Lifecore Biomedical Inc. (LFCR) Q1 2026 Earnings: EPS Misses Estimates, Stock DeclinesOperating Margin Analysis - DonanımHaber
How (LFCR) Movements Inform Risk Allocation Models - Stock Traders Daily
LFCR Q1 2026 Earnings: EPS Misses Estimates by a Wide Margin, Stock Edges HigherAnnual Report - dars.gov.et
Lifecore Biomedical Inc (LFCR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lifecore Biomedical Inc (LFCR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lifecore Biomedical Inc (LFCR) Institutional Confidence - TradingKey
Lifecore Biomedical Inc (LFCR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
0.30%
2.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):